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Objectives: Systemic glucocorticoids are widely used in companion animals. This study
aimed to estimate the frequency, describe the characteristics and to evaluate risk factors
for common side effects to systemic glucocorticoid therapy in dogs under primary
veterinary care in the UK.
Methods: A cohort study using VetCompassTM data from 455,557 dogs under
primary veterinary care during 2013 estimated the frequency of side effects to systemic
glucocorticoid therapy occurring within 31 days of therapy. Risk factors for the most
common side effects, polyuria and polydipsia (PUPD), were evaluated using multivariable
logistic regression modeling (P < 0.05).
Results: During 2013, 28,472 study dogs received systemic glucocorticoids (6.2%,
95% CI 6.2–6.3). Review of the records of 3,000 randomly selected treated dogs
identified 148 (4.9%, 95% CI 4.2–5.7%) dogs with at least one side effect recorded
within 31 days of therapy. The most frequent side effects were polydipsia (39.2% of
total presenting signs), polyuria (28.4%), vomiting (16.2%) and diarrhea (14.9%), dogs
receiving only oral systemic glucocorticoids (odds ratio, OR: 3.72) and dogs receiving
both oral and injectable systemic glucocorticoid (OR: 10.71) had increased odds of
PUPD compared with dogs receiving only injectable systemic glucocorticoid. Focusing
on the active substance used, treatment with prednisolone tablets only (OR: 3.53)
and treatment with both prednisolone tablets and injectable dexamethasone sodium
phosphate (OR: 7.62) showed increased odds of PUPD compared to treatment with
injectable dexamethasone sodium phosphate only.
Brief: These results can assist veterinarians to optimize therapeutic selection for reduced
side effect, to inform owners on common side effects, and help protect the welfare of
pets and their owners.
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INTRODUCTION
Glucocorticoids are commonly used in companion
animal veterinary practice as anti-inflammatory and
immunosuppressive agents (1, 2). However, glucocorticoids have
been associated with various side effects, including vomiting,
diarrhea, bodyweight gain or loss, polyuria, polydipsia, delayed
wound healing, behavioral problems, immunosuppression and
predisposition to infection (3, 4).
There is some published evidence on side effects that
may occur following systemic glucocorticoid usage. Systemic
glucocorticoid treatment has been associated with predisposition
to infection (5, 6) immunosuppression and decreased urine
osmolality (1, 2, 7). Glucocorticoid treatment has been
associated with increased risk of urinary tract infection
among dogs with skin disease (5, 6, 8). Dogs administered
long-term hydrocortisone showed side effects including
thinning of skin, PUPD (9). Another study reported
increased surgical complications, diarrhea and urinary tract
infection in dogs with acute thoracolumbar intervertebral disk
herniation treated with dexamethasone before surgery compared
with dogs treated with other glucocorticoids (10). Dogs treated
with dexamethasone and methylprednisolone acetate have
also been reported to have an increased risk of hepatopathy
(11). Despite this qualitative evidence, there is little published
quantitative evidence on the frequency or risk factors for side
effects following systemic glucocorticoids therapy.
Anonymised clinical data from primary-care veterinary
practices offers potential to investigate the frequency of side
effects following glucocorticoid therapy (12). Previous studies
within the VetCompassTM Programme used data collected from
primary-care small animal practices to quantify the usage of
glucocorticoids in dogs but did not report on side effects (13, 14).
The current study aimed to estimate the frequency and describe
the characteristics of side effects to systemic glucocorticoid
therapy recorded in the electronic clinical records from a large
population of dogs under primary veterinary care in the UK. The
study further aimed to evaluate risk factors for PUPD as side
effects in dogs treated with systemic glucocorticoids.
METHODS
The VetCompass Programme collates de-identified electronic
patient record (EPR) data from primary-care veterinary practices
in the UK (15). VetCompass collects information fields with
relevant dates that include species, breed, date of birth, sex, neuter
status, insurance status, bodyweight, clinical notes and treatment.
The EPR data were extracted from practice management systems
using integrated clinical queries and uploaded to the VetCompass
database (16).
A retrospective cohort study of dogs attending VetCompass
practices was used to estimate the frequency and risk factors
Abbreviations: BSAVA, British Small Animal Veterinary Association; EPR,
electronic patient record; IQR, interquartile range; NOAH, National Office for
Animal Heath; OR, odds ratio; PUPD, polyuria and polydipsia; VMD, Veterinary
Medicines Directorate.
for PUPD after systemic glucocorticoid therapy. The sampling
frame for the study included dogs under veterinary care during
2013 that had at least one EPR within the VetCompass database
from January 1st 2013 to December 31st 2013 and/or at least one
EPR both before and after this period. Sample size calculations
estimated that ∼3,000 dogs would be required to be studied in
order to detect a 0.5% side effects frequency (with a precision
of ± 0.25% confidence limit and 95% confidence level). Ethical
approval was granted by the RVC Ethics andWelfare Committee
(URN 2015 1369).
A systemic glucocorticoid treatment was defined as any
glucocorticoid preparation administered by injection, dispensed
as oral tablets or an oral suspension. Inclusion criteria
required that a systemic glucocorticoid was either administered
or dispensed during 2013. Animals receiving only topical
glucocorticoid therapy were excluded from consideration. A
comprehensive list of chemical and brand names for systemic
glucocorticoids was generated by searching the Veterinary
Medicines Directorate (17), British Small Animal Veterinary
Association (BSAVA) formulary (18) and National Office for
Animal Heath (NOAH) veterinary products databases (19).
A list of search terms was derived from these chemical and
brand names to identify all systemic glucocorticoids within
the treatment field of the VetCompass database. Case-finding
involved initial screening of the treatment fields of all dogs within
the study population for any treatment record that may have
been a systemic glucocorticoid based on these search terms. A list
of animal unique identification codes for these candidate cases
for systemic glucocorticoid usage was generated and treatment
data (date, drug, volume of injectable/number of tablets, dosage
instructions) on all treatments during 2013 were extracted from
the VetCompass database to an Excel format. Duplicates were
removed and all remaining dispensing terms used were manually
coded as systemic glucocorticoid (yes/no) to create a master list
of systemic glucocorticoid dispensing terms. Data were extracted
to describe the name of the active substance, dosage and route of
administration of glucocorticoids used.
For the current study, a side effect case was defined as a dog
with evidence in the clinical notes of a side effect within 31 days
of a new episode of systemic glucocorticoid usage during 2013.
This period was selected to allow for manifestation of potentially
delayed onset side-effects whilst reducing the inclusion of
potential side-effect events unrelated to glucocorticoid therapy.
It was required that there was no evidence in the clinical notes
of the observed potential side effect(s) in the 31 days prior to
the new systemic glucocorticoid episode. A new episode was
defined as systemic glucocorticoid usage that was not preceded
by systemic glucocorticoid therapy during the previous 31 days.
Individual treatment episodes could include the usage of multiple
systemic glucocorticoid products and dogs could have multiple
treatment episodes during 2013. All dogs that received at least
one systemic glucocorticoid during 2013 were randomly ordered
and the EPRs of a random sample of 3,000 of these dogs were
manually reviewed in detail to identify all dogs that met the side
effects case definition. Data were extracted for identified side
effects cases to describe the dates of the start of the episode of
systemic glucocorticoid usage and the first reported side effect,
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the clinical sign(s) of the side effect, the clinical action(s) taken
in response to the side effect and the main clinical indication
for the systemic glucocorticoid originally prescribed in the side
effects cases.
The period (days) of glucocorticoid administration prior to
the side effect was calculated from the glucocorticoid episode
start date to the first reported side effect. Initial duration of
systemic glucocorticoid prescribed for side effects cases was
extracted from the treatment data field. The initial daily systemic
glucocorticoid dosage (mg/kg/day) was calculated from the total
daily dose for each glucocorticoid from the treatment data field
and dividing by the bodyweight.
A breed variable included individual breeds with 60 or more
systemic glucocorticoid cases in the random sample of 3,000
dogs, a grouped category of all remaining purebreds and a general
grouping of crossbred dogs. This approach was taken to allow
focus on commonly affected breeds and to facilitate statistical
power for the individual breed analyses (20). A purebred variable
categorized all dogs of recognizable breeds as “purebred” and the
remaining dogs as “crossbred” (21). Age (years) was calculated
for side effect cases at the date of first administration of the
systemic glucocorticoid episode for the relevant side effects
and for non-case dogs at the date of administration of a
randomly selected systemic glucocorticoid event during 2013.
An age variable categorized age (years) into four groups (≤ 2.0,
> 2.0 to ≤ 5.0, > 5.0 to ≤ 8.0, > 8.0 years). Bodyweight
(kg) described the nearest bodyweight recorded during 2013 to
the date of the systemic glucocorticoid usage episode for dogs
≥ 18 months and the nearest bodyweight recorded within 1
month to the systemic glucocorticoid usage episode date for
dogs≤ 18 month. A bodyweight variable categorized bodyweight
into six groups (0.0–10.0, > 10.0–20, > 20.0–30, > 30.0–
40 kg, ≥ 40.0 kg, unavailable). Route of administration and active
substance variables were defined for side effects cases on all
systemic glucocorticoid products used within a maximum of 31
days from the start of the systemic glucocorticoid episode up
to the onset of a side effect. For non-case dogs, these data were
extracted for treatment within 31 days of the start of a systemic
glucocorticoid episode that was randomly selected from all
systemic glucocorticoid episodes for that dog. A season variable
defined the season of treatment based on the age date defined
above and categorized into winter (December to February),
summer (June to August), autumn (September to November)
and spring (March to May).
Following data checking and cleaning in Excel (Microsoft
Office Excel 2013, Microsoft Corp.), analyses were conducted
using Stata Version 14 (Stata Corporation). Numerical data
were assessed graphically for normality and summarized with
median (interquartile range, IQR) or mean (standard deviation)
as appropriate (22). Risk factor analysis evaluated the 3,000
randomly selected dogs treated with at least one systemic
glucocorticoid to compare PUPD cases with the non- PUPD
dogs. These two side effects were considered closely related
therefore any dog with at least one of these PUPD side effects
was included in the study. Logistic regression modeling was
used to evaluate univariable associations between risk factors
and PUPD outcome. Risk factors with liberal associations
TABLE 1 | Main clinical indications for systemic glucocorticoid usage in 148 side
effects cases recorded within 31 days after receiving systemic glucocorticoid
therapy among dogs under primary veterinary care in the UK. Some cases had
multiple indications.
Clinical
category
Main clinical indication No. side
effects (%)
Total (%)
Skin Dermatitis 38 (24.7) 50 (32.5)
Pyoderma 5 (3.2)
Insect bite 2 (1.3)
Skin problem (not specified and
other)
5 (3.2)
Otic problem otitis 28 (18.2) 29 (18.8)
Ear lipoma 1 (0.6)
Gastro-intestinal
tract
Diarrhea 8 (5.2) 20 (13)
Vomiting 4 (2.6)
Vomiting and gastritis 1 (0.6)
Vomiting and dermatitis 1 (0.6)
Constipation 1 (0.6)
Inflammation bowel disease 2 (1.3)
Stomach ulcer 1 (0.6)
Gastrointestinal problem (not
specified)
2 (1.3)
Neoplasia Abdominal tumor 2 (1.3) 13 (8.4)
Lung neoplasia 3 (1.9)
Prostatic carcinoma 2 (1.3)
Mast cell tumor 1 (0.6)
Oral and pharyngeal tumors 2 (1.3)
Mammary adenocarcinoma 1 (0.6)
Cancer (not specified) 2 (1.3)
Respiratory Coughing 3 (1.9) 11 (7.1)
Bacterial pneumonia 1 (0.6)
Lung fibrosis 1 (0.6)
Lung consolidation 1 (0.6)
Brachycephalic Obstructive
Airway Syndrome (BOAS)
1 (0.6)
Bronchitis 1 (0.6)
Coughing and ventral oedema, 1 (0.6)
Kennel cough 1 (0.6)
Rhinitis due to allergy 1 (0.6)
Other After surgery
(hemimandibulectomy to remove
tumor)
2 (1.3) 11 (7.1)
Allergy 2 (1.3)
Anal gland inflammation 4 (2.6)
Cyst in limb 1 (0.6)
Lethargic 1 (0.6)
Prostate problem 1 (0.6)
Nervous system CNS inflammatory diseases 2 (1.3) 10 (6.5)
Spinal impingement 2 (1.3)
Tremors (cause not specified) 1 (0.6)
Seizure 1 (0.6)
Vestibular syndrome 4 (2.6)
Autoimmune Autoimmune myositis 1 (0.6) 4 (2.6)
Immune mediated anemia 2 (1.3)
Immune-mediated
thrombocytopenia
1 (0.6)
Skeletal Arthritis 3 (1.9) 4 (2.6)
Mandible bony swelling 1 (0.6)
Adrenal Addison’s disease 2 (1.3) 2 (1.3)
Total 154
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in univariable modeling (P < 0.3) were taken forward for
mixed effects multivariable logistic regression modeling using
a manual backwards-stepwise elimination method. Residual
interclass correlation coefficients were assessed, clinic was
evaluated as a random effect and pair-wise interaction effects
were evaluated for the final model variables. Two multivariable
models were developed to alternatively evaluate two strongly
biologically correlated variables of interest separately: route
of administration of the steroids and active substances
used. The Hosmer-Lemeshow test for goodness of fit was
conducted for assessment of the fit of the final fixed effects
multivariable model (23). Final statistical significance was set
at P < 0.05.
RESULTS
The study population included 455,557 dogs from 304 clinics
in the VetCompass database under veterinary care during
2013. Of these, 28,472 dogs received at least one systemic
glucocorticoid during 2013 giving an overall one-year period
prevalence for systemic glucocorticoid usage of 6.2% (95% CI
6.2–6.3). From a random sample of 3,000 dogs receiving systemic
glucocorticoids during 2013 that were reviewed in detail, 148
dogs were identified with at least one side effect within 31
days of administration, giving a side effects occurrence among
dogs receiving systemic glucocorticoids of 4.9% (95% CI 4.2–
5.7%). Of these 148 side effects reported, 97 (65%) occurred
within the first 14 days after initiation of therapy. None of
the side effects cases had more than one event of side effect
during 2013.
The most common clinical categories leading to prescribing
of systemic glucocorticoid to the 148 side effects cases were
skin conditions (n = 50, 32.5%), ear problems (33, 21.4%) and
gastro-intestinal tract problems (20, 13.0%) (Table 1). The most
common clinical indications were dermatitis (38, 24.7%) and
ear infections (28, 18.2%). Prednisolone 5mg was the most
common oral systemic glucocorticoid prescribed for dogs with
a side effect without a preceding systemic glucocorticoid injection,
with a median initial daily dosage of 0.67 mg/kg/day (Table 2).
Similarly, prednisolone 5mg was themost common oral systemic
glucocorticoid prescribed for side effect cases with a preceding
systemic glucocorticoid injection (median initial daily dosage of
0.48 mg/kg/day). Dexamethasone sodium phosphate was the
most common injectable systemic glucocorticoid used in side
effects cases (median initial daily dosage 0.10 mg/kg/day). The
duration of dispensed treatments for side effects cases varied with
active substance and formulation type though was generally for a
median duration of∼2–3 weeks (Table 3).
The period to onset of the side effects varied across
side effect cases. For prednisolone administrations without
preceding injection, the median duration between start of
glucocorticoid treatment and the development of side effects
varied from 10.5 to 13 days, whilst methylprednisolone had a
median onset of 4.5 days, though this was based on only 4
events (Table 4). Dexamethasone sodium phosphate, the most
commonly administered injectable systemic glucocorticoid, had
a median onset to side effects of 7 days based on a single injection
course for all these events.
There were 241 clinical signs recorded in the EPR within the
148 side effects cases (Table 5). Some side effects cases had more
than one clinical sign recorded. No fatality was reported. The
most frequent clinical signs reported for side effects cases were
polydipsia (58 events, 39.2% of the side effects cases), polyuria
(42, 28.4%), vomiting (24, 16.2%), diarrhea (22, 14.9%) and
polyphagia (20, 13.5%). The dose of the systemic glucocorticoid
was subsequently reduced in 43 (29.1%) side effects cases whilst
therapy was discontinued in 25 (16.9%) side effects cases.
Seventy-one dogs had either PUPD. Of these, 53 (75.71%)
were purebred and 40 (56.34%) were male. PUPD cases had
a median bodyweight of 19.1 kg (IQR 10.8–30.4) and median
age was 6.9 years (IQR 4.2–10.2), (Table 6). The most common
breeds among the PUPD cases were Labrador Retriever (8/71,
11.27%), West Highland White Terrier (4/71, 5.63%), Boxer
(4/71, 5.63%), along with crossbred dogs (17/71, 23.94%)
(Table 6). Of the non-cases dogs, 2266 (77.55%) were purebred,
1630 (55.65%) were male. The median bodyweight for non-
cases was 14.3 kg (IQR 8.6–25.0) and the median age was 4.9
years (IQR 2.1–8.3). The most common breeds among the non-
case dogs were Staffordshire Bull Terrier 23 0 (7.85%), Labrador
Retriever (179, 6.11%), Jack Russell Terrier (178, 6.08%) as well
as crossbreds 593 (20.25%).
Univariable logistic regression identified four of nine tested
variables that were liberally associated with PUPD and
were further evaluated using multivariable logistic regression
modeling: age, route of administration, active substance and
neuter status. Add in the ones that were dropped also. There is
strong biological correlation between route of administration and
active substance so these were evaluated in separate multivariable
modeling that resulted in two final models.
The final model that focused on route of administration
retained 2 variables: route of administration and age. After
accounting for the effects of the age, dogs that had both oral
and injectable systemic glucocorticoids (OR: 10.40 95% CI 4.76–
22.75) and dogs that had oral systemic glucocorticoids (OR: 3.69
95% CI 1.84–7.42) showed increased odds of PUPD compared
with dogs that had injectable systemic glucocorticoids only
(Table 7). Dogs aged > 8 years had 4.24 times the odds (95%
CI 1.62–11.09) of PUPD compared with dogs aged ≤ 2 years.
No biologically significant interactions were identified. Clinic was
not significant as a random effect (P-value= 0.252). There was no
evidence of poor fit in the final fixed effect multivariable model
(Hosmer-Lemeshow P-value= 0.789).
The final model that focused on active substance also retained
two variables: active substance and age. Dogs treated with
prednisolone tablets only had 3.44 (95% CI 1.54–7.73) times
the odds of a PUPD compared with dogs that had injectable
dexamethasone sodium phosphate only (Table 8). Dogs treated
with both prednisolone tablets and injectable dexamethasone
sodium phosphate had 7.29 (95% CI 2.86–18.60) times the odds
of PUPD compared with dogs that had injectable dexamethasone
sodium phosphate alone. Dogs aged > 8 years had 4.38
times the odds (95% CI 1.67–11.47) of PUPD compared with
dogs aged ≤ 2 years. Clinic was not significant as a random
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TABLE 2 | Initial dosages of systemic glucocorticoid active substances that had a side effect recorded within 31 days after receiving systemic glucocorticoid therapy
among dogs under primary veterinary care in the UK (n = 120).
Active substance No. dogs Median IQR Range Expected duration
(injectable)
Oral tablets without injection (mg/kg daily)
Prednisolone 1mg 2 (1.4) 0.14 0.11–0.17 0.11–0.17
Prednisolone 5mg 58 (39.2) 0.67 0.44–0.92 0.20–2.22
Prednisolone 25mg 12 (8.1) 0.89 0.65–1.29 0.40–2.50
Methylprednisolone 4 (2.7) 0.97 0.63–1.94 0.47–2.74
Prednisolone/cinchophen 1 (0.7) 0.12
Overall tablets without injection (mg/kg daily) 77 (52.0) 0.7 0.46–1.0 0.11–2.74
Tablets with prior injection (mg/kg daily)
Prednisolone 5mg 6 (4.1) 0.48 0.37–0.54 0.20–0.75
Prednisolone 25mg 1 (0.7) 0.89
Overall tablets with prior injection (mg/kg daily) 7 (4.7) 0.52 0.37–0.75 0.20–0.89
Injectable (mg/kg daily)
Dexamethasone isonicotinate 3 (2.0) 0.10 0.07–0.11 0.07–0.11 Intermediate
Dexamethasone phenylpropionate, dexamethasone sodium phosphate 9 (6.1) 0.07 0.06–0.09 0.05–0.20 Short to intermediate
Dexamethasone sodium phosphate 23 (15.5) 0.10 0.09–0.17 0.07–0.86 Short
Methylprednisolone acetate 1 (0.7) 2.27 Long
Overall injectables (mg/kg daily) 36 (24.3) 0.10 0.08–0.15 0.05–2.27
Total 120
Twenty-eight cases were missing bodyweight data so the daily dosage was not available.
TABLE 3 | Duration of systemic glucocorticoid active substances dispensed for oral treatments that had a side effect recorded within 31 days after receiving systemic
glucocorticoid therapy among dogs under primary veterinary care in the UK (n = 148).
Active substance No. dogs (% of side effect cases) Median (days) IQR Range (days)
Oral tablets without preceding injection
Prednisolone 1mg 4 (2.7) 22.5 14.5–60 14–90
Prednisolone 5mg 61 (41.2) 15.0 12–30 4–180
Prednisolone 25mg 15 (10.1) 14.0 10–28 7–120
Methylprednisolone 4 (2.7) 36.5 19–59 14–69
Prednisolone/cinchophen 1 (0.7) 10
Overall tablets without preceding injection 85 (57.4) 15.0 12–30 4–180
Oral tablets with preceding injection
Prednisolone 5mg 12 (8.1) 10.0 6.0–16.5 4–31
Prednisolone 25mg 2 (1.4) 21.0 20–22 20–22
Overall tablets with preceding injection 14 (9.5) 11.5 7.0–20 4–31
effect (P-value = 0.198). No biologically significant interactions
were identified and there was no evidence of poor fit in
the final fixed effect multivariable model (Hosmer-Lemeshow
P-value= 0.579).
DISCUSSION
This is the first study to explore side effects to systemic
glucocorticoids in dogs attending primary-care practices by
analyzing clinical records from a multi-center primary-care
research database. The study identified that nearly 5% of dogs
receiving a systemic glucocorticoid had evidence of a side effect
recorded in the EPR within 31 days of onset of therapy.
Of the 148 side effects cases identified, none had more than
one side effect event during 2013, suggesting that veterinarians
may have taken steps to avoid recurrent side effect events
to systemic glucocorticoids in known susceptible animals.
Immediate clinical actions in response to side effects identified
in the current study, included reduction of the glucocorticoid
dose (29.1% of side effect events) and discontinuation of therapy
(16.9% of side effect events). For consistency of the study, cases
were only evaluated for the first course where side-effects were
reported, though it would have been interesting to evaluate the
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TABLE 4 | Period (days) from commencing systemic glucocorticoid treatment to developing a side effect for dogs under primary veterinary care in the UK (n = 148).
Active substance No. dogs (%) Median (days) IQR Range (days)
Oral tablets without preceding injection
Prednisolone 1mg 4 (2.7) 11 5.0–15.5 3.0–16
Prednisolone 5mg 65 (43.9) 13 7.0–18.0 1.0–30
Prednisolone 25mg 16 (10.8) 10.5 6.5–19.0 4.0–25
Methylprednisolone 4 (2.7) 4.5 1.0–13.5 0–20
Prednisolone/cinchophen 1 (0.7) 5
Overall tablets without preceding injection 90 (60.8) 12.5 7.0–18.0 0–30
Tablets with preceding injection
Prednisolone 5mg 12 (8.1) 9 6.0–9.5 3.0–20
Prednisolone 25mg 2 (1.4) 1.5 0–3.0 0–3.0
Overall tablets with preceding injection 14 (9.5) 8 3.0–9.0 0–20
Injectable only
Dexamethasone Isonicotinate 3 (2.0) 7 6.0–21 6.0–21
Dexamethasone phenylpropionate, dexamethasone sodium phosphate 11 (7.4) 17 11–24 2.0–28
Dexamethasone sodium phosphate 29 (19.6) 7 4.0–14 1.0–31
Methylprednisolone Acetate 1 (0.7) 6
Overall injectables 44 (29.7) 8 5.5–20 1.0–31
Total 148
TABLE 5 | Frequency (%) of presenting signs among 148 dogs under primary
veterinary care with side effects recorded within 31 days after receiving systemic
glucocorticoid therapy.
Side effect Frequency % of side effects dogs
Polydipsia 58 39.2
Polyuria 42 28.4
Vomiting 24 16.2
Diarrhea 22 14.9
Polyphagia or increased appetite 20 13.5
Weight gain 18 12.2
Weight loss 14 9.5
Anorexia 11 7.4
Lethargy 10 6.8
Panting 8 5.4
Hair loss or alopecia 3 2.0
Behavioral change 3 2.0
Growling 3 2.0
Shaking 3 2.0
Mastitis 1 0.7
Delayed wound healing 1 0.7
Total 241
Some dogs had more than one presenting sign recorded.
number of these dogs that had subsequent courses within the
study period.
Skin (32.5%) and ear (21.4%) conditions were the most
common indications for prescribing systemic glucocorticoids
where a side effect was subsequently observed. However,
these findings are not conclusive evidence for a side effect
predisposition by condition because the clinical indication for
the non-side effect dogs was not studied, but it does suggest
that this may be a useful future line of research. Many skin
and ear disorders have an inflammatory or immune-mediated
component that may benefit from systemic glucocorticoid
therapy and consequently systemic glucocorticoids are routinely
recommended for these conditions by dermatologists (24). A
study using primary-care practice data in the UK reported
that 20% of dermatology cases were prescribed systemic
glucocorticoid therapy (25).
Prednisolone was the most commonly prescribed oral
systemic glucocorticoid among the side effects cases. A previous
study for the whole population of dogs under primary veterinary
care in 2013 using VetCompass data reported similar results
(14). The median prednisolone initial daily dosage was between
0.14 and 0.89 mg/kg/day, depending on tablet size. These
were within the recommended manufacturer dosages of 0.1–
2.0 mg/kg/day (2017). The short-acting agent, dexamethasone
sodium phosphate, was the most commonly administered
injectable systemic glucocorticoids among the side effects cases
with a median daily dose of 0.10 mg/kg/day. Other injectable
glucocorticoids, dexamethasone isonicotinate, dexamethasone
phenylpropionate with dexamethasone sodium phosphate and
methylprednisolone acetate were also used and are considered
intermediate, short to intermediate and long acting respectively,
so are less suitable for initiation of a combination therapy
“injectable followed by oral treatment” plan. However, just under
5% of side effects occurred after injectable combined with oral
glucocorticoid treatment were administered.
The median time to side effect after initiation of oral
glucocorticoid therapy alone was 12.5 days, whilst side effects
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TABLE 6 | Descriptive analysis and univariable logistic regression results for risk factors for polyuria and/or polydipsia within 31 days after receiving systemic
glucocorticoid therapy among dogs under primary veterinary care in the UK.
Variable Category Case No.
(%)
Non-case No.
(%)
Odds
ratio
95% CI Category
P-value
Variable P-value
Purebred status Crossbred 17 (24.29) 656 (22.45) Base 0.719
Purebred 53 (75.71) 2266 (77.55) 0.9 0.52–1.57 0.716
Common breeds Crossbreed 17 (23.94) 593 (20.25) Base 0.39
Boxer 4 (5.63) 61 (2.08) 2.29 0.75–7.01 0.148
Bichon 3 (4.23) 67 (2.29) 1.56 0.45–5.47 0.486
Labrador Retriever 8 (11.27) 179 (6.11) 1.56 0.66–3.67 0.31
German Shepherd Dog 3 (4.23) 71 (2.42) 1.47 0.42–5.15 0.544
Lhasa Apso 2 (2.82) 59 (2.01) 1.18 0.27–5.24 0.825
Border Collie 2 (2.82) 62 (2.12) 1.13 0.25–4.98 0.877
Cavalier King Charles Spaniel 0 68 (2.32) Empty
Cocker Spaniel 3 (4.23) 111 (3.79) 0.94 0.27–3.27 0.926
West Highland White Terrier 4 (5.63) 171 (5.84 0.82 0.27–2.46 0.718
Shih Tzu 2 (2.82) 97 (3.31) 0.72 0.16–3.16 0.663
Yorkshire Terrier 2 (2.82) 105 (3.58) 0.66 0.15–2.92 0.588
Staffordshire Bull Terrier 3 (4.23) 230 (7.85) 0.45 0.13–1.57 0.212
Jack Russell Terrier 1 (1.41) 178 (6.08) 0.20 0.03–1.48 0.114
Other purebred 17 (23.94) 877 (29.94) 0.68 0.34–1.34 0.26
Sex Female 31 (43.66) 1295 (44.21) Base 0.918
Male 40 (56.34) 1630 (55.65) 1.03 0.64–1.65 0.918
Age (years)a ≤2.0 5 (7.04) 713 (24.47) Base <0.001
2.0–≤5.0 20 (28.17) 808 (27.73) 3.53 1.32–9.45 0.012
5.0–≤8.0 17 (23.94) 615 (21.11) 3.94 1.45–10.75 0.007
>8.0 29 (40.85) 778 (26.70) 5.32 2.05–13.81 0.001
Bodyweight (kg)b ≤10.0 12 (16.90) 810 (27.65) Base 0.319
>10.0–20 17 (23.94) 739 (25.23) 1.55 0.74–3.27 0.247
>20.0–30 13 (18.31) 429 (14.65) 2.05 0.93–4.52 0.077
>30.0–40 9 (12.68) 266 (9.08) 2.28 0.95–5.48 0.064
>40 5 (7.04) 134 (4.57) 2.52 0.87–7.26 0.087
Not recorded 15 (21.13) 551 (18.81) 1.84 0.85–3.96 0.120
Route of systemic
glucocorticoid
administration (within 31
days)
Injectable 10 (14.08) 1,353 (46.19) Base <0.001
Oral 42 (59.15) 1,349 (46.06) 4.21 2.10–8.43 <0.001
Both oral and injectable 19 (26.76) 227 (7.75) 11.32 5.20–24.67 <0.001
Active systemic
glucocorticoid substance
(Within 31 days)
Injectable: Dexamethasone Sodium
Phosphate
7 (9.86) 805 (27.48) Base <0.001
Injectable: Dexamethasone
Phenylpropionate, Dexamethasone
Sodium Phosphate
2 (2.82) 457 (15.60) 0.5 0.10–2.43 0.393
Other injectable only 2 (2.82) 92 (3.14) 2.5 0.51–12.21 0.258
Oral: Methylprednisolone 0 120 (4.10) Empty
Oral: Prednisolone 44 (61.97) 1,233 (42.10) 4.1 1.84–9.16 <0.001
Oral: Prednisolone- and injectable
Dexamethasone Sodium Phosphate
13 (18.31) 184 (6.28) 8.12 3.20–20.65 <0.001
Other oral and injectable
combinations
3 (4.23) 38 (1.30) 9.08 2.26–36.49 <0.001
Season Winter 14 (19.72) 621 (21.20) Base 0.075
Spring 24 (33.80) 609 (20.79) 1.75 0.9–3.41 0.102
Autumn 17 (23.94) 780 (26.63) 0.97 0.47–1.98 0.926
Summer 16 (22.54) 919 (31.38) 0.77 0.37–1.59 0.484
Neuter status Entire 13 (18.31) 981 (33.49) 0.018
Neutered 50 (70.42) 1,671 (57.05) 2.26 1.22–4.18 0.009
Unrecorded 8 (11.27) 277 (9.46) 2.18 0.89–5.31 0.087
aAge at having a side effect for cases and age at a random treatment for non-cases.
bWithin 31 days of treatment for dogs <18 month and any body weight in 2013 for adults.
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TABLE 7 | Final model 1: Multivariable logistic regression results with route of administration as the focus for risk factors for polyuria and polydipsia within 31 days after
receiving systemic glucocorticoid therapy among dogs under primary veterinary care in the UK.
Variable Category Odds ratio 95% CI Category P-value Variable P-value
Route of administration
(within 31 days)
Injectable Base <0.001
Oral 3.69 1.84–7.42 <0.001
Both oral and injectable 10.4 4.76–22.75 <0.001
Age (years) ≤2.0 Base 0.005
2.1–5.0 3.13 1.16–8.44 0.024
5.1–8.0 3.23 1.18–8.86 0.023
>8.0 4.24 1.62–11.09 0.003
TABLE 8 | Final model 2: Multivariable logistic regression results with active substance as the focus for risk factors for polyuria and polydipsia within 31 days after
receiving systemic glucocorticoid therapy among dogs under primary veterinary care in the UK.
Variable Category Odds ratio 95% CI Category P-value Variable P-value
Active substance (within 31
days)
Injectable: Dexamethasone
Sodium Phosphate
Base <0.001
Injectable: Dexamethasone
Phenylpropionate,
Dexamethasone Sodium
Phosphate
0.45 0.09–2.19 0.325
Other injectable only 2.15 0.44–10.58 0.345
Oral: Methylprednisolone Empty
Oral: Prednisolone 3.44 1.54–7.73 0.003
Oral and injectable:
Prednisolone-Dexamethasone
Sodium Phosphate
7.29 2.86–18.60 <0.001
Other oral and injectable 7.13 1.76–28.92 0.006
Age (years) ≤ 2.0 Base
2.1–5.0 3.17 1.17–8.54 0.023 0.004
5.1–8.0 3.38 1.23–9.29 0.018
>8.0 4.38 1.67–11.47 0.003
appeared to occur sooner when an injectable agent was
administered either alone or with oral therapy, at a median of
8 days after onset of therapy. Injectable glucocorticoid therapy is
likely to reach a higher plasma concentration sooner and hence
any side effects might be expected to become evident sooner
(3). However, there was a wide range in onset across agents
and this reflects the variable nature of the side effects reported,
such that certain side effects may occur more immediately
after administration of the systemic glucocorticoids (e.g., PUPD)
whilst others require prolonged exposure to occur (e.g., hair
loss/alopecia) (26).
The two most frequent side effects to systemic glucocorticoids
recorded in the current study were polydipsia (39.2%) and
polyuria (28.4%). For this reason, factors associated with these
side effects were explored more deeply in the analysis. These
side effects likely result from the effect of glucocorticoids on the
antidiuretic hormone (ADH) leading to excessive loss of fluids
in urine and enhancing feeling of thirst to replace fluid loss
(26). Polydipsia and polyuria can promote urinary incontinence
by increasing bladder fill beyond the physiological thresholds
of the urinary sphincter (27). Urinary incontinence has been
considered to negatively impact on the welfare of affected
dogs (28). Within the 31 day period PUPD were frequently
reported however, urinary incontinence was not observed in
the records.
The next most frequent side effect in the current study
were vomiting (16.2%) and diarrhea (14.9%). Vomiting is
associated with unpleasant nausea sensations, while profuse
or prolonged vomiting can cause dehydration, electrolyte
and acid-base imbalances that may require hospitalization
(29, 30). Many human surgical patients report nausea and
vomiting to be more distressing than the postsurgical pain (31).
Behavioral changes (3 cases) and growling (3 cases) contributed
4% to the side effects cases in the current study. Previous
study found an association between corticosteroids therapy
and dog behavioral problems (4). In this study aggression
toward people was the most recorded behavioral side effect.
Therefore, as well as side effects to systemic glucocorticoids
being relatively common, the results of the current study
suggest that the clinical signs induced by these side effects
can have substantial negative impacts for both owners and
their dogs.
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Dogs over 8 years old were more than 4 times more likely
to have PUPD following systemic glucocorticoid treatment
compared to dogs aged under 2 years. Increasing predisposition
to incontinence (32) and chronic kidney disease (27) as dogs age
may promote increased PUPD in older dogs. An experimental
study reported higher liver enzymes and pathological hepatic
changes in older dogs after glucocorticoids therapy compared
to young dogs (33). Overall, these findings suggest that
veterinarians should be especially vigilant about prescribing
systemic glucocorticoids to older dogs. Sex did not appear to
be associated with side-effects in the current study. A previous
study that reported increased susceptibility of acquired urinary
incontinence in neutered bitches compared to male dogs and
this may suggest increased risk of PUPD in female dogs (28).
However, the small number of cases may have underpowered the
current study in identifying this association.
Dogs treated with oral systemic glucocorticoids had 3.69
times the odds, and dogs treated with both oral and injectable
systemic glucocorticoids had 10.40 times the odds, of PUPD
compared to dogs treated only with an injectable systemic
glucocorticoid. Similarly, dogs receiving oral prednisolone alone
had 3.44 times the odds, and dogs receiving a combination of oral
prednisolone with injectable dexamethasone sodium phosphate
had 7.29 times the odds of PUPD than dogs that received
injectable dexamethasone sodium phosphate alone. The current
results suggest prolonged and combination therapy compared
to single injectable glucocorticoid administration may result in
increased probability of PUPD. In humans, oral therapies are
associated with prolonged exposure and maintenance of blood
levels of these drugs and therefore suggest that the cumulative
effect over time may be a strong contributor to PUPD risk
(32, 34).
The data resource used for this study had some limitations
as previously reported (13, 35). These EPR data were not
recorded primarily for research purposes and thus were limited
by reliance on accurate and thorough record-keeping by the
clinicians. It was assumed all side effects would be recorded by
the attending veterinarians, though it is possible that common
side effects may not have been recorded, due to the anticipation
of such side effects, suggesting that the current results may
underestimate the frequency of complications. Owners’ previous
experience of expected side effects from using glucocorticoids
may additionally have led to reduced reporting to the veterinarian
and additional under-reporting of side effects. Furthermore,
chronic side effects that may have happened after 31 days
of receiving systemic glucocorticoid treatment were likely to
be underreported. However, it was considered evaluation of
a shorter period after therapy/acute side effects here would
reduce the risk that side-effects reported were unrelated to the
glucocorticoid therapy administered.
This study was limited by the low power in identifying PUPD
due to small number of cases in some categories leading to
data sparsity. The study did not analyse data on concurrently
administered medications (for example drugs with ulcerogenic
or nephrotoxic potential such as NSAIDs) due to the variability
in co-therapies used, the range of associated potential side effects
and the limited sample size for the PUPD risk factor study
undertaken. Nor did the study attempt to extract data on the
overall health status of the dogs due to challenges identifying this
information consistently within the clinical records of all 3,000
dogs. It is acknowledged these factors in particular could have
confounded in part the associations reported and further work
would ideally incorporate these variables within the analyses.
Clinical indications for the use of systemic glucocorticoids
were extracted only for the side effects cases and not for the
overall population of dogs treated with systemic glucocorticoids.
Knowledge of the prescribed daily doses (mg/kg) could have
helped to define the intended therapeutic effect (high “shock”
dose, immunosuppression, anti-inflammatory daily, or alternate
days) as well as allow evaluation of an association with dose.
However, dosage instructions frequently varied within each
animal over time (e.g., start one tablet twice a day reduce to one
daily then to one every other day) making extraction of these data
difficult. Finally, given the study was based on data from 2013 it is
possible current available systemic glucocorticoids have changed.
Nonetheless, the range ofmost common systemic glucocorticoids
would appear to be broadly comparable, suggesting the study
remains relevant (18).
In conclusion, this is the first study to estimate the
frequency of side effects and risk factors for PUPD to
systemic glucocorticoids occurring with 31 days of treatment
in a large general population of dogs attending primary-care
practices in UK. The results highlight that combination systemic
glucocorticoid therapy and prolonged treatments were associated
with increased risk of recording PUPD. Older dogs were at most
risk of PUPD. These results can help veterinarians to optimize
decision-making when prescribing systemic glucocorticoids for
dogs in order to reduce the risks of side effects and to protect the
welfare of both dogs and their owners.
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